STARNSEStrides Pharma Science Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 1 Jun, 2026 · 17:25 IST

Arco Lab to Pivot Path demerger scheme becomes effective from June 1

Nclt Scheme FiledStrategic Transactions View source PDFExplain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.3%Reaction day
₹1092.70
prior close
₹1094.00
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.1%-2.4% vs market
Pharmaceuticals peers, median of 164sector-0.3%-1.1% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.4
10m
-1.2
15m
-0.8
30m
-1.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.3+1.1-2.4-0.3-1.1
Next day
-1.2+1.3-2.6-0.3-1.0
2d
-6.0+2.2-8.2-0.3-5.7
3d
-5.1+2.2-7.3+0.3-5.3
4d
-8.3+0.2-8.5-0.7-7.6
5d
-6.5+2.1-8.6+0.5-7.0
1w
-9.3-0.5-8.8-0.5-8.8
15d
+1.6+7.5-5.9+4.7-3.1
1m
+3.3+8.6-5.3+6.0-2.7
2m
-6.2+9.1-15.4+6.4-12.6
3m
-4.2+11.8-15.9+7.6-11.8
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Strides Pharma Science informed that the Scheme of Demerger of the Identified Business of Arco Lab Private Limited into Pivot Path Private Limited has become effective from June 1, 2026. The NCLT Bengaluru Bench had approved the scheme, and the certified copy of the order was received on May 25, 2026. The filing was made by Strides as the listed parent or group entity.

Likely market impact

Group-level restructuring between Arco Lab and Pivot Path is now complete. No direct financial impact on Strides shareholders is specified in this intimation.